Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE for the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

\*\*Complete if Known\*\*

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/751,072

Filing Date January 2, 2004

First Named Inventor Euykerman et al.

Group An Unit 1645

Examiner Name To be assigned

Attorney Docket Number 2676-6264US

(use as many sheets as necessary)
Sheet 1 of 2

U.S. PATENT DOCUMENTS						
Examiner Initials *	g.,	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cohumns, Lines, Where Relevant Passages or Relevant Figures Appear	
	Cite No. <sup>1</sup>	Number - Kind Code <sup>2</sup> (if known)				
311	l. 1	US-5,525,490	08-11-1998	Erickson et al.		
01		US- 5,637,463	06-10-1997	Dalton et al.		
$\neg \tau$		US- 5,733,726	03-31-1998	Fu et al.		
		US- 6,303,319 B1	10-16-2001	Rickles		
-		US- 6,479,280 B1	14-12-2002	Muyldermans et al.		
$\overline{V}$	7	US- 2002/0019006 A1	02-14-2002	Yuan et al.		

		FOREIGN :	PATENT DO	CUMENTS		
Examiner Initials*	Cite No. 1	Foreign Patent Document  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cohimns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
311	1.	FR 2 782 084 A1	02-11-2000	Centre National de la Recherche Scientifique CNRS		
211		EP 1 088 892 A1	04-04-2001	Vlaams Interuniversitair Instituut voor Biotechnologie VZW		_
311		WO 90/02809	03-22-1990	Protein Engineering Corporation		
311		WO 92/20791	11-26-1992	Cambridge Antibody Technology Limited		
311		WO 95/26400	10-05-1995	Onyx Pharmaceuticals, Inc.		
0311		WO 97/10330	03-20-1997	Bioinvent International AB		
211		WO 97/31113	08-28-1997	Ariad Pharmaceuticals, Inc.		
311		WO 97/32017	09-04-1997	Morphosys Gesellschaft fur Proteinoptimierung MBH		
311		WO 98/13502	04-02-1998	ICOS Corporation		
3/4		WO 99/66324	12-23-1999	Joly et al.		
311		WO 00/46406	08-10-2000	Alphagene, Inc.		
311		WO 00/07014	02-10-2000	Vlaams Interuniversitair Instituut voor Biotechnologie VZW		
311		WO 00/08148	02-17-2000	Association Pour le Develooppement de l'immunologie Moleculaire		
341		WO 03/004643 A2	01-16-2003	Vlaams Interuniversitair Instituut voor Biotechnologie VZW		[/]

		<u> </u>		
Examiner Signature .	Bach &	toward	Date Considered	12-13-2004

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control mumber

Complete if Known **Application Number** 10/751,072 INFORMATION DISCLOSURE Filing Date January 2, 2004 STATEMENT BY APPLICANT Euykerman et al. First Named Inventor Group Art Unit 1645 (use as many sheets as necessary) **Examiner Name** To be assigned of 2 Attorney Docket Number 2676-6264US

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS					
Examiner Cite No.1		[ (cook, magazine, journal, serial, symposium, cutalog, ctc.), cute, page(s), volume-issue minior(s), page		7	Γ <sup>2</sup>
3H			EYCKERMAN et al., Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor, FEBS Letters, 2000, pp. 33-37, Vol. 486.	1	
3H			FASHENA et al., The continued evolution of two-hybrid screening approaches in yeast: how to outwit different preys with different baits, Gene, 2000, pp. 1-14, Vol. 250.		
311			LI et al., Leptin receptor activation of SH2 domain containing protein tyrosine phosphatase 2 modulates Ob receptor signal transduction, Proc. Natl. Acad. Sci., August 1999, pp. 9677-82, Vol. 96, USA.		
34			OSBORNE et al., The Yeast Tribrid System-Genetic Detection of trans-phosphorylated ITAM-SH2-Interactions, Bio/technology, December 1995, pp 1474-78, Vol. 13.		
			PGT International Scarch Report, PC17Er02/07419, dated December 20, 2002.	7	
~				7	
<				-	
				-	
			·		<u> </u>
	1	-		_	

Examiner Signature Howard Considered 12-13-2004
---

\*EXAMINER: Initial is reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known **Application Number** 10/751,072 INFORMATION DISCLOSURE Filing Date January 2, 2004 STATEMENT BY APPLICANT First Named Inventor Euykerman et al. Group Art Unit 1645 (use as many sheets as necessary) **Examiner Name** To be assigned Attorney Docket Number 2676-6264US

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
		PCT International Preliminary Examination Report, PCT/EP02/07419, dated February 10, 2004.	
_			
,			
	·		
, ,	· ·		

Examiner Signature	3nd	Howard Date Considered	12/13/2004
			· · · · · · · · · · · · · · · · · · ·

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

+

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.